Merck KGaA and Pfizer sign combo immunotherapy treatment deal 03-Aug-2018 By Maggie Lynch Leap Therapeutics partners with Merck KGaA and Pfizer for Phase I/II clinical trial for immunotherapy regime for solid tumors.